Search results

ANSTO today welcomed a significant Federal Government funding allocation to further safeguard the production of life-saving nuclear medicines in Australia.

ANSTO manufacture and supply a range of radiopharmaceuticals, radiochemicals, kits and accessories for use in research, industry and the health sector.

The nuclear medicine community has welcomed the Australian Government’s decision to provide $30 million in funding to ANSTO for the design of a new nuclear medicine manufacturing facility.

ANSTO showcased its significant contribution to security, safety, and public health during a visit of the Director-General of the International Atomic Energy Agency (IAEA) Rafael Grossi, Minister for Industry and Science Ed Husic, Australian Ambassador to Austria Richard Sinclair and Ambassador for Arms Control and Counter-Proliferation Ian Biggs and other dignitaries at the weekend.

The Australian Nuclear Science and Technology Organisation (ANSTO) has joined a team, lead by the US Department of Energy’s Pacific Northwest National Laboratory (PNNL), to install a high resolution monitoring system at ANSTO’s medical isotope production facility in Lucas Heights, Australia.

The new facility will be built around a product line of ANSTO’s design – a new Technetium-99m generator – that will enable greater process automation than is possible with existing technology, leading to improvements in efficiency, quality and importantly the highest levels of production safety.

ANSTO’s OPAL multi-purpose research reactor at Lucas Heights has officially returned to power and recommenced operations, following a months-long planned shutdown to carry out essential maintenance and upgrades.

See details of previously published customer updates from our Health products team. 

Read about an ANSTO scientist and their work to prepare for a school project or interview.

Australia’s new state-of-the-art nuclear medicine facility gets green light.

The Government is safeguarding Australia’s sovereign capability to produce vital nuclear medicines by launching a $30 million project to design a new world-leading manufacturing facility to be built at Lucas Heights in Sydney.

ANSTO’s nuclear medicine processing and distribution facility assembles, loads, tests and distributes a range of nuclear medicine products, including Mo-99. The Mo-99 is dispensed into an ANSTO radiopharmaceutical Gentech® Generator where it decays to Tc-99m.

Planning is now underway for a second repatriation project which is scheduled to take place in 2022. Find out more information.

Australia’s nuclear agency ANSTO is continuing to lead planning efforts to repatriate what is called a TN-81 cask of intermediate-level radioactive from the United Kingdom in 2022.

Australia’s new Mo-99 manufacturing facility reaches practical completion